inVentiv Health Consulting Landmark Study

2014 Dealmakers' Intentions Study

Now in its sixth year, the inVentiv Health Consulting (formerly Campbell Alliance) Dealmakers’ Intentions Study is the only forward-looking measure of dealmaking activity in the pharmaceutical and biotech industries.  While there are many quality sources of information that look historically at past deal trends, this survey offers a prospective view of the partnering and licensing landscape for the year ahead.

In the first quarter of 2014, inVentiv Consulting surveyed 99 licensing professionals, capturing expectations for deal activity, supply and demand for assets at different stages of development, and approaches to valuation. The results of that survey provide a forward-looking view into what dealmakers anticipate will happen in licensing and acquisitions over the upcoming year. The results of the 2014 Dealmakers’ Intentions Study suggest a narrowing of the discount rate, coupled with a strong IPO market, contributing to tempered optimism for M&A/licensing deal activity looking forward into the second half of 2014. The market for dealmaking appears to be softening, and, as such, both buyers and sellers are likely going to need to modify their approach given the potential headwinds.

Dealmakers’ Intentions presents conclusions that are crucial for C-suite executives, as well as executives responsible for dealmaking strategy and the business development function.

A summary of the study results will be presented during our Super Session at the BIO International ConventionPharmaceutical Executive magazine also hosts an editorial roundtable to highlight the study; the article is slated for the July issue.

Results from prior Dealmakers' Intentions studies can be found in our Landmark Studies section.

inVentiv Health Consulting offers world class healthcare consulting services.